BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu Z, Pothula SP, Wilson JS, Apte MV. Pancreatic cancer and its stroma: A conspiracy theory. World J Gastroenterol 2014; 20(32): 11216-11229 [PMID: 25170206 DOI: 10.3748/wjg.v20.i32.11216] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 79] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Thakur AK, Nigri J, Lac S, Leca J, Bressy C, Berthezene P, Bartholin L, Chan P, Calvo E, Iovanna JL, Vasseur S, Guillaumond F, Tomasini R. TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma. Cell Death Differ 2016;23:1358-70. [PMID: 26943320 DOI: 10.1038/cdd.2016.18] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
2 De Blasio A, Vento R, Di Fiore R. Mcl-1 targeting could be an intriguing perspective to cure cancer. J Cell Physiol 2018;233:8482-98. [PMID: 29797573 DOI: 10.1002/jcp.26786] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
3 Schernberg A, Vernerey D, Goldstein D, Van Laethem JL, Glimelius B, van Houtte P, Bonnetain F, Louvet C, Hammel P, Huguet F. Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma. Int J Radiat Oncol Biol Phys 2021;110:1022-31. [PMID: 33548338 DOI: 10.1016/j.ijrobp.2021.01.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Meng H, Nel AE. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer. Adv Drug Deliv Rev 2018;130:50-7. [PMID: 29958925 DOI: 10.1016/j.addr.2018.06.014] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
5 Fiorino S, Bacchi-reggiani ML, Birtolo C, Acquaviva G, Visani M, Fornelli A, Masetti M, Tura A, Sbrignadello S, Grizzi F, Patrinicola F, Zanello M, Mastrangelo L, Lombardi R, Benini C, Di Tommaso L, Bondi A, Monetti F, Siopis E, Orlandi PE, Imbriani M, Fabbri C, Giovanelli S, Domanico A, Accogli E, Di Saverio S, Grifoni D, Cennamo V, Leandri P, Jovine E, de Biase D. Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. Pancreatology 2018;18:122-32. [DOI: 10.1016/j.pan.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
6 Song H, Song J, Kim YJ, Jeong HH, Min HJ, Koh SS. DCPP1 is the mouse ortholog of human PAUF that possesses functional analogy in pancreatic cancer. Biochem Biophys Res Commun 2017;493:1498-503. [PMID: 28988106 DOI: 10.1016/j.bbrc.2017.10.015] [Reference Citation Analysis]
7 Zhao YR, Zhang LF, Zhao P, Zhou L. Clinical significance of expression of miR216a, CSK and JAK2 in pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2015; 23(34): 5458-5464 [DOI: 10.11569/wcjd.v23.i34.5458] [Reference Citation Analysis]
8 Mei L, Du W, Ma WW. Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. J Gastrointest Oncol. 2016;7:487-494. [PMID: 27284483 DOI: 10.21037/jgo.2016.03.03] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
9 Li Y, Zhao Z, Liu H, Fetse JP, Jain A, Lin CY, Cheng K. Development of a Tumor-Responsive Nanopolyplex Targeting Pancreatic Cancer Cells and Stroma. ACS Appl Mater Interfaces 2019;11:45390-403. [PMID: 31769963 DOI: 10.1021/acsami.9b15116] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
10 Hsueh CT, Selim JH, Tsai JY, Hsueh CT. Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(31): 7080-7090 [PMID: 27610018 DOI: 10.3748/wjg.v22.i31.7080] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
11 Saito K, Sakaguchi M, Maruyama S, Iioka H, Putranto EW, Sumardika IW, Tomonobu N, Kawasaki T, Homma K, Kondo E. Stromal mesenchymal stem cells facilitate pancreatic cancer progression by regulating specific secretory molecules through mutual cellular interaction. J Cancer. 2018;9:2916-2929. [PMID: 30123360 DOI: 10.7150/jca.24415] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
12 Idichi T, Seki N, Kurahara H, Yonemori K, Osako Y, Arai T, Okato A, Kita Y, Arigami T, Mataki Y, Kijima Y, Maemura K, Natsugoe S. Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma. Oncotarget 2017;8:53180-93. [PMID: 28881803 DOI: 10.18632/oncotarget.18261] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
13 Čunderlíková B. Clinical significance of immunohistochemically detected extracellular matrix proteins and their spatial distribution in primary cancer. Critical Reviews in Oncology/Hematology 2016;105:127-44. [DOI: 10.1016/j.critrevonc.2016.04.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Liot S, Balas J, Aubert A, Prigent L, Mercier-Gouy P, Verrier B, Bertolino P, Hennino A, Valcourt U, Lambert E. Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins. Front Immunol 2021;12:612271. [PMID: 33889150 DOI: 10.3389/fimmu.2021.612271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Bhaw-Luximon A, Jhurry D. New avenues for improving pancreatic ductal adenocarcinoma (PDAC) treatment: Selective stroma depletion combined with nano drug delivery. Cancer Lett. 2015;369:266-273. [PMID: 26415628 DOI: 10.1016/j.canlet.2015.09.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
16 Coppola S, Carnevale I, Danen EHJ, Peters GJ, Schmidt T, Assaraf YG, Giovannetti E. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. Drug Resist Updat 2017;31:43-51. [PMID: 28867243 DOI: 10.1016/j.drup.2017.07.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
17 Monkman JH, Thompson EW, Nagaraj SH. Targeting Epithelial Mesenchymal Plasticity in Pancreatic Cancer: A Compendium of Preclinical Discovery in a Heterogeneous Disease. Cancers (Basel) 2019;11:E1745. [PMID: 31703358 DOI: 10.3390/cancers11111745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
18 Pothula SP, Xu Z, Goldstein D, Merrett N, Pirola RC, Wilson JS, Apte MV. Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. Oncotarget 2017;8:76722-39. [PMID: 29100344 DOI: 10.18632/oncotarget.20822] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
19 Takaji R, Yamada Y, Matsumoto S, Kiyonaga M, Hongo N, Mori H, Hijiya N, Ohta M, Inomata M, Takaki H, Fukuzawa K, Yonemasu H. Small pancreatic ductal carcinomas on triple-phase contrast-enhanced computed tomography: enhanced rims and the pathologic correlation. Abdom Radiol (NY) 2018;43:3374-80. [PMID: 29796845 DOI: 10.1007/s00261-018-1645-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Hackeng WM, Hruban RH, Offerhaus GJ, Brosens LA. Surgical and molecular pathology of pancreatic neoplasms. Diagn Pathol 2016;11:47. [PMID: 27267993 DOI: 10.1186/s13000-016-0497-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 9.7] [Reference Citation Analysis]
21 Crawley AS, O'Kennedy RJ. The need for effective pancreatic cancer detection and management: a biomarker-based strategy. Expert Rev Mol Diagn 2015;15:1339-53. [PMID: 26394703 DOI: 10.1586/14737159.2015.1083862] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
22 Logsdon DP, Grimard M, Luo M, Shahda S, Jiang Y, Tong Y, Yu Z, Zyromski N, Schipani E, Carta F, Supuran CT, Korc M, Ivan M, Kelley MR, Fishel ML. Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. Mol Cancer Ther 2016;15:2722-32. [PMID: 27535970 DOI: 10.1158/1535-7163.MCT-16-0253] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
23 Pan L, Zhou L, Yin W, Bai J, Liu R. miR-125a induces apoptosis, metabolism disorder and migrationimpairment in pancreatic cancer cells by targeting Mfn2-related mitochondrial fission. Int J Oncol. 2018;53:124-136. [PMID: 29749475 DOI: 10.3892/ijo.2018.4380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
24 Al-Assar O, Bittner MI, Lunardi S, Stratford MR, McKenna WG, Brunner TB. The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells. Radiother Oncol 2016;119:300-5. [PMID: 27247056 DOI: 10.1016/j.radonc.2016.03.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
25 Koido S, Okamoto M, Shimodaira S, Sugiyama H. Wilms’ tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. Immunotherapy 2016;8:1309-20. [DOI: 10.2217/imt-2016-0031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
26 Li T, Li H, Li S, Xu S, Zhang W, Gao H, Xu H, Wu C, Wang W, Yu X, Liu L. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Cancer Med 2019;8:5223-31. [PMID: 31339230 DOI: 10.1002/cam4.2430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
27 Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: Surgery is not enough. World J Gastroenterol 2015; 21(11): 3157-3165 [PMID: 25805920 DOI: 10.3748/wjg.v21.i11.3157] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 80] [Article Influence: 12.3] [Reference Citation Analysis]
28 Gopinathan A, Morton JP, Jodrell DI, Sansom OJ. GEMMs as preclinical models for testing pancreatic cancer therapies. Dis Model Mech 2015;8:1185-200. [PMID: 26438692 DOI: 10.1242/dmm.021055] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 10.3] [Reference Citation Analysis]
29 Mukaida N, Sasaki S. Fibroblasts, an inconspicuous but essential player in colon cancer development and progression. World J Gastroenterol 2016; 22(23): 5301-5316 [PMID: 27340347 DOI: 10.3748/wjg.v22.i23.5301] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
30 Ren B, Liu X, Suriawinata AA. Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: Histopathology, Cytopathology, and Molecular Pathology. Am J Pathol. 2019;189:9-21. [PMID: 30558727 DOI: 10.1016/j.ajpath.2018.10.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
31 Lu Z, Weniger M, Jiang K, Boeck S, Zhang K, Bazhin A, Miao Y, Werner J, D'Haese JG. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Target Oncol 2018;13:447-59. [PMID: 30062609 DOI: 10.1007/s11523-018-0578-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
32 Kim SI, Shin JY, Park JS, Jeong S, Jeon YS, Choi MH, Choi HJ, Moon JH, Hwang JC, Yang MJ, Yoo BM, Kim JH, Lee HW, Kwon CI, Lee DH. Vascular enhancement pattern of mass in computed tomography may predict chemo-responsiveness in advanced pancreatic cancer. Pancreatology 2017;17:103-8. [PMID: 27780664 DOI: 10.1016/j.pan.2016.10.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
33 Jiang B, Zhou L, Lu J, Wang Y, Liu C, You L, Guo J. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?Front Oncol. 2020;10:576399. [PMID: 33178608 DOI: 10.3389/fonc.2020.576399] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
34 Zhang YJ, Wen CL, Qin YX, Tang XM, Shi MM, Shen BY, Fang Y. Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance. Oncol Rep 2017;38:3335-46. [PMID: 29039610 DOI: 10.3892/or.2017.6026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
35 Estaras M, Gonzalez A. Modulation of cell physiology under hypoxia in pancreatic cancer. World J Gastroenterol 2021; 27(28): 4582-4602 [PMID: 34366624 DOI: 10.3748/wjg.v27.i28.4582] [Reference Citation Analysis]
36 Liu D, Steins A, Klaassen R, van der Zalm AP, Bennink RJ, van Tienhoven G, Besselink MG, Bijlsma MF, van Laarhoven HWM. Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma. Biomedicines 2020;8:E444. [PMID: 33105540 DOI: 10.3390/biomedicines8110444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Falasca M, Kim M, Casari I. Pancreatic cancer: Current research and future directions. Biochim Biophys Acta. 2016;1865:123-132. [PMID: 26794394 DOI: 10.1016/j.bbcan.2016.01.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
38 Malhotra P, Palanisamy R, Falasca M. Targeting pancreatic ductal adenocarcinoma: New therapeutic options for the ongoing battle. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00174-0. [PMID: 34535394 DOI: 10.1016/j.hbpd.2021.09.004] [Reference Citation Analysis]
39 Melstrom LG, Salazar MD, Diamond DJ. The pancreatic cancer microenvironment: A true double agent. J Surg Oncol 2017;116:7-15. [PMID: 28605029 DOI: 10.1002/jso.24643] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
40 Ebata N, Fujita M, Sasagawa S, Maejima K, Okawa Y, Hatanaka Y, Mitsuhashi T, Oosawa-Tatsuguchi A, Tanaka H, Miyano S, Nakamura T, Hirano S, Nakagawa H. Molecular Classification and Tumor Microenvironment Characterization of Gallbladder Cancer by Comprehensive Genomic and Transcriptomic Analysis. Cancers (Basel) 2021;13:733. [PMID: 33578820 DOI: 10.3390/cancers13040733] [Reference Citation Analysis]
41 Leppänen J, Lindholm V, Isohookana J, Haapasaari KM, Karihtala P, Lehenkari PP, Saarnio J, Kauppila JH, Karttunen TJ, Helminen O, Huhta H. Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Pancreas 2019;48:43-8. [PMID: 30451798 DOI: 10.1097/MPA.0000000000001195] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
42 Vaiphei K. Molecular interphase between extracellular matrix & cancer cells. Indian J Med Res 2017;146:298-300. [PMID: 29355134 DOI: 10.4103/ijmr.IJMR_1601_16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Adamska A, Domenichini A, Capone E, Damiani V, Akkaya BG, Linton KJ, Di Sebastiano P, Chen X, Keeton AB, Ramirez-Alcantara V, Maxuitenko Y, Piazza GA, De Laurenzi V, Sala G, Falasca M. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. J Exp Clin Cancer Res 2019;38:312. [PMID: 31378204 DOI: 10.1186/s13046-019-1308-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
44 Li X, Xiao Y, Fan S, Xiao M, Wang X, Zhu X, Chen X, Li C, Zong G, Zhou G, Wan C. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma. Human Pathology 2016;57:182-92. [DOI: 10.1016/j.humpath.2016.07.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
45 Pei Y, Chen L, Huang Y, Wang J, Feng J, Xu M, Chen Y, Song Q, Jiang G, Gu X, Zhang Q, Gao X, Chen J. Sequential Targeting TGF‐β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer. Small 2019;15:1900631. [DOI: 10.1002/smll.201900631] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
46 Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18. [PMID: 28640192 DOI: 10.3390/ijms18071338] [Cited by in Crossref: 210] [Cited by in F6Publishing: 198] [Article Influence: 42.0] [Reference Citation Analysis]
47 Li M, Guo H, Wang Q, Chen K, Marko K, Tian X, Yang Y. Pancreatic stellate cells derived exosomal miR-5703 promotes pancreatic cancer by downregulating CMTM4 and activating PI3K/Akt pathway. Cancer Lett 2020;490:20-30. [PMID: 32585413 DOI: 10.1016/j.canlet.2020.06.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
48 Yonemori K, Seki N, Kurahara H, Osako Y, Idichi T, Arai T, Koshizuka K, Kita Y, Maemura K, Natsugoe S. ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. Cancer Sci 2017;108:124-35. [PMID: 27862697 DOI: 10.1111/cas.13119] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
49 Görte J, Danen E, Cordes N. Therapy-Naïve and Radioresistant 3-Dimensional Pancreatic Cancer Cell Cultures Are Effectively Radiosensitized by β1 Integrin Targeting. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02728-0. [PMID: 34481933 DOI: 10.1016/j.ijrobp.2021.08.035] [Reference Citation Analysis]
50 Gnatenko DA, Kopantsev EP, Sverdlov ED. The role of the signaling pathway FGF/FGFR in pancreatic cancer. Biochem Moscow Suppl Ser B 2017;11:101-10. [DOI: 10.1134/s1990750817020032] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
51 Kalayarasan R, Narayanan S, Sahoo J, Mohan P. Impact of surgery for chronic pancreatitis on the risk of pancreatic cancer: Untying the Gordian knot. World J Gastroenterol 2021; 27(27): 4371-4382 [PMID: 34366610 DOI: 10.3748/wjg.v27.i27.4371] [Reference Citation Analysis]
52 Hurtado M, Sankpal UT, Ranjan A, Maram R, Vishwanatha JK, Nagaraju GP, El-Rayes BF, Basha R. Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. Crit Rev Oncol Hematol 2018;126:201-7. [PMID: 29759562 DOI: 10.1016/j.critrevonc.2018.03.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
53 Lafaro KJ, Melstrom LG. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment. Am J Pathol 2019;189:44-57. [PMID: 30558722 DOI: 10.1016/j.ajpath.2018.09.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
54 Xu Z, Pang TCY, Liu AC, Pothula SP, Mekapogu AR, Perera CJ, Murakami T, Goldstein D, Pirola RC, Wilson JS, Apte MV. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. Br J Cancer 2020;122:1486-95. [PMID: 32203220 DOI: 10.1038/s41416-020-0782-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
55 Ghanaatgar-kasbi S, Khorrami S, Avan A, Aledavoud SA, Ferns GA. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma. CPD 2019;24:4619-25. [DOI: 10.2174/1381612825666190110145855] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
56 Javle M, Golan T, Maitra A. Changing the course of pancreatic cancer--Focus on recent translational advances. Cancer Treat Rev 2016;44:17-25. [PMID: 26924195 DOI: 10.1016/j.ctrv.2016.01.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
57 Quiroz-Reyes AG, Islas JF, Delgado-Gonzalez P, Franco-Villarreal H, Garza-Treviño EN. Therapeutic Approaches for Metastases from Colorectal Cancer and Pancreatic Ductal Carcinoma. Pharmaceutics 2021;13:103. [PMID: 33466892 DOI: 10.3390/pharmaceutics13010103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Takaji R, Yamada Y, Shimada R, Matsumoto S, Daa T, Endo Y, Inomata M, Asayama Y. Retrospective evaluation of venous phase contrast-enhanced computed tomography images in patients who developed pancreatic adenocarcinomas after treatment for nonpancreatic primary cancer. BJR Open 2021;3:20200069. [PMID: 34381945 DOI: 10.1259/bjro.20200069] [Reference Citation Analysis]
59 Karaca M, Dutta R, Ozsoy Y, Mahato RI. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer. Mol Pharm 2016;13:1822-32. [PMID: 26981724 DOI: 10.1021/acs.molpharmaceut.5b00971] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
60 Banerjee S, Modi S, McGinn O, Zhao X, Dudeja V, Ramakrishnan S, Saluja AK. Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer. Clin Cancer Res 2016;22:415-25. [PMID: 26405195 DOI: 10.1158/1078-0432.CCR-15-1155] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
61 Liu C, Wang JO, Zhou WY, Chang XY, Zhang MM, Zhang Y, Yang XH. Long non-coding RNA LINC01207 silencing suppresses AGR2 expression to facilitate autophagy and apoptosis of pancreatic cancer cells by sponging miR-143-5p. Mol Cell Endocrinol 2019;493:110424. [PMID: 30991076 DOI: 10.1016/j.mce.2019.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
62 Pothula SP, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Key role of pancreatic stellate cells in pancreatic cancer. Cancer Lett. 2016;381:194-200. [PMID: 26571462 DOI: 10.1016/j.canlet.2015.10.035] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 9.7] [Reference Citation Analysis]
63 Guerrero PE, Duran A, Ortiz MR, Castro E, Garcia-Velasco A, Llop E, Peracaula R. Microfibril associated protein 4 (MFAP4) is a carrier of the tumor associated carbohydrate sialyl-Lewis x (sLex) in pancreatic adenocarcinoma. J Proteomics 2021;231:104004. [PMID: 33038510 DOI: 10.1016/j.jprot.2020.104004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
64 Huang H, Zhou W, Chen R, Xiang B, Zhou S, Lan L. CXCL10 is a Tumor Microenvironment and Immune Infiltration Related Prognostic Biomarker in Pancreatic Adenocarcinoma. Front Mol Biosci 2021;8:611508. [PMID: 33681290 DOI: 10.3389/fmolb.2021.611508] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
65 Zhang X, Schönrogge M, Eichberg J, Wendt EHU, Kumstel S, Stenzel J, Lindner T, Jaster R, Krause BJ, Vollmar B, Zechner D. Blocking Autophagy in Cancer-Associated Fibroblasts Supports Chemotherapy of Pancreatic Cancer Cells. Front Oncol 2018;8:590. [PMID: 30568920 DOI: 10.3389/fonc.2018.00590] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
66 Kota J, Hancock J, Kwon J, Korc M. Pancreatic cancer: Stroma and its current and emerging targeted therapies. Cancer Lett. 2017;391:38-49. [PMID: 28093284 DOI: 10.1016/j.canlet.2016.12.035] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 16.6] [Reference Citation Analysis]
67 Long J, Liu Z, Hui L. Anti-tumor effect and mechanistic study of elemene on pancreatic carcinoma. BMC Complement Altern Med 2019;19:133. [PMID: 31215421 DOI: 10.1186/s12906-019-2544-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
68 Liu Y, Du L. Role of pancreatic stellate cells and periostin in pancreatic cancer progression. Tumour Biol 2015;36:3171-7. [PMID: 25840689 DOI: 10.1007/s13277-015-3386-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
69 Klau M, Mayer P, Bergmann F, Maier-hein K, Hase J, Hackert T, Kauczor H, Grenacher L, Stieltjes B. Correlation of Histological Vessel Characteristics and Diffusion-Weighted Imaging Intravoxel Incoherent Motion–Derived Parameters in Pancreatic Ductal Adenocarcinomas and Pancreatic Neuroendocrine Tumors: . Investigative Radiology 2015;50:792-7. [DOI: 10.1097/rli.0000000000000187] [Cited by in Crossref: 41] [Cited by in F6Publishing: 17] [Article Influence: 5.9] [Reference Citation Analysis]
70 Chakladar J, Kuo SZ, Castaneda G, Li WT, Gnanasekar A, Yu MA, Chang EY, Wang XQ, Ongkeko WM. The Pancreatic Microbiome is Associated with Carcinogenesis and Worse Prognosis in Males and Smokers.Cancers (Basel). 2020;12. [PMID: 32962112 DOI: 10.3390/cancers12092672] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
71 Han DH, Kang CM, Lee SW, Hwang HK, Lee WJ. A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer. Oncol Lett 2017;14:4225-30. [PMID: 28943931 DOI: 10.3892/ol.2017.6696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
72 Meng Z, Ren D, Zhang K, Zhao J, Jin X, Wu H. Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pancreatic adenocarcinoma. Aging (Albany NY) 2020;12:5048-70. [PMID: 32181755 DOI: 10.18632/aging.102931] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
73 Wang S, Chen J, Li H, Qi X, Liu X, Guo X. Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD82 Cell Line. Technol Cancer Res Treat 2021;20:15330338211045204. [PMID: 34605330 DOI: 10.1177/15330338211045204] [Reference Citation Analysis]
74 Lee JH, Woo SM, Hong EK, Park SJ, Han SS, Kim TH, Lee JH, Lee WJ. Cytopathological results of initial endoscopic ultrasound-guided fine needle aspiration for primary mass and prognosis in pancreatic cancer patients. Cytopathology 2019;30:173-8. [PMID: 30570774 DOI: 10.1111/cyt.12675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Reinert CP, Baumgartner K, Hepp T, Bitzer M, Horger M. Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase. Abdom Radiol (NY) 2020;45:750-8. [PMID: 31953587 DOI: 10.1007/s00261-020-02406-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
76 Swierczewska M, Kozlov S, Adiseshaiah PP. Emerging Technologies for the Diagnosis and Treatment of Pancreatic Cancer. Oncogenomics. Elsevier; 2019. pp. 313-27. [DOI: 10.1016/b978-0-12-811785-9.00022-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Hadden M, Mittal A, Samra J, Zreiqat H, Sahni S, Ramaswamy Y. Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression.BiochimBiophysActa Rev Cancer. 2020;1874:188418. [PMID: 32827581 DOI: 10.1016/j.bbcan.2020.188418] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
78 Pothula SP, Xu Z, Goldstein D, Biankin AV, Pirola RC, Wilson JS, Apte MV. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. Br J Cancer. 2016;114:269-280. [PMID: 26766740 DOI: 10.1038/bjc.2015.478] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
79 Vincent P, Bruza P, Palisoul SM, Gunn JR, Samkoe KS, Hoopes PJ, Hasan T, Pogue BW. Visualization and quantification of pancreatic tumor stroma in fresh tissue via ultraviolet surface excitation. J Biomed Opt 2021;26. [PMID: 33423407 DOI: 10.1117/1.JBO.26.1.016002] [Reference Citation Analysis]
80 Su T, Yang B, Gao T, Liu T, Li J. Polymer nanoparticle-assisted chemotherapy of pancreatic cancer. Ther Adv Med Oncol 2020;12:1758835920915978. [PMID: 32426046 DOI: 10.1177/1758835920915978] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]